Leadership Team
T-CURX's leadership team combines decades of experience in drug development and clinical research, gained at leading pharmaceutical and biotech companies including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, MorphoSys, NBE Therapeutics, Sotio, Vivoryon Therapeutics, and Takeda.
Ulf Grawunder, PhD
Chief Executive Officer & Co-FounderUlf is a serial entrepreneur with more than 20 years of experience in building biotechnology companies from foundation to a successful exit. He previously co-founded 4-Antibody AG (acquired by Agenus) and NBE-Therapeutics (acquired by Boehringer Ingelheim).
Prof. Michael Hudecek, MD
Chief Medical Officer & Co-FounderMichael is an internationally renowned expert in adoptive cellular and CAR T cell-based cancer therapies. He has published more than 60 peer-reviewed papers in the field and is a co-inventor on more than 10 patents and applications.
Paulina Paszkiewicz, PhD
Director BD & Program ManagementPaulina is a business development and program management expert with over 15 years of experience in CAR-T research, medical affairs, and business strategy, including leadership roles at Bristol Myers Squibb and Nanologica AB, and a PhD in tumor immunology.
Florian Schmid
Chief Financial OfficerFlorian brings more than 20 years of financial leadership experience across biopharma, technology, and consulting, including a Nasdaq IPO and multiple follow-on financings. Before joining T-CURX, he served as CFO of iOmx Therapeutics and Vivoryon Therapeutics.
Sabrina Müller, PhD
Director Research & DevelopmentSabrina is a seasoned R&D leader with over nine years of experience in developing innovative immunotherapeutics in leadership roles at MorphoSys and Bristol Myers Squibb, and deep expertise in cellular immunology and tumor microenvironment dynamics.
Jan Van den Brulle, PhD
VP External Research & DevelopmentJan is a seasoned R&D expert with over 20 years of experience in biotech, including leadership roles at MorphoSys and Sloning Biotech, where he advanced therapeutic antibody programs and commercialized a proprietary DNA synthesis technology.
Frank Richard, MD
Vice President MedicalFrank is an experienced clinical pharmacologist with over 20 years in oncology drug development, including leadership roles at Heidelberg Pharma and SOTIO Biotech, and expertise in digitalization and AI in pharma.
Andreas Geissler, PhD
Director Intellectual PropertyAndreas is a European and German Patent Attorney with over 20 years of experience in life sciences IP, having led IP strategy at Medigene and Leukocare AG, and combining scientific expertise in chemistry and molecular cell biology with legal and commercial acumen.
Christian Söllner
General CounselChristian is an experienced legal advisor with more than 30 years of experience in corporate and commercial law. He founded his own law firm in 2004 and has supported T-CURX with legal expertise since its inception.